Trickle Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (608)	5/18/2001 5:45:44 PM
From: tuck	Read Replies (1) of 1784

Just got back from Reudi Aebersold's talk on methods of analysis in proteomics. I was listening mainly with respect to what tools would be used. Although Dr. Aebersold agrees with the litany that there is no platform technology for proteomics in the way that sequencers are the workhorses of genomics, every method he mentioned involved the use of LC/MS/MS. Some techniques require more front end steps in the form of chemical tweaking (labeling) of the analytes for abundance studies, to additional fractionation steps to make less complicated mixtures (in a nutshell, because complex mixtures reduce speed/sensitivity of the MS techniques (more noise)). If that's all he sees on the horizon, it appears to Trickle that manufacturers of LC/MS/MS set-ups are where it's at in proteomics. And a boost in sales of digesters and fractionating stuff. The techniques he talked of are more expensive than 2-D gels, but have much more dynamic range (for finding those rare proteins) and analytical power. There are limitations, but it's still the best technique out there for the foreseeable future, and the Dr. Aebersold's of the world are putting a lot of effort into refining it. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next